Valneva Se · EURONEXT:VLA
Valneva — Investor Presentation (January 2026)
26 slides from Valneva's investor presentation, January 2026
Slide 1: A Leading Specialty Vaccine Company
A Leading Specialty Vaccine Company January 2026
Slide 2: Disclaimer
Disclaimer This presentation does not contain or constitute an offer of, or the solicitation of an offer Certain information and statements included in this presentation are not historical facts to buy or subscribe for, Valneva SE shares to any person in the USA or in any jurisdiction to but are for
Slide 3: A Leading Specialty Vaccine Company: Focused on vaccines that make a difference
Cash-Generating Specialty Vaccines Business: Proprietary travel vaccines: IXIARO®, DUKORAL®, IXCHIQ® A Leading Specialty Vaccine Company: Blockbuster Clinical Catalyst: Focused on vaccines that VLA15 (Lyme disease) partnered with Pfizer; significant unmet need with make a difference Phase 3 readout
Slide 4: Valneva's Commercial and R&D Portfolio
Valneva’s Commercial and R&D Portfolio A unique, differentiated portfolio Program Design/Description Pre-Clinical Phase 1 Phase 2 Phase 3 VLA15: World’s most clinically advanced Lyme Lyme disease vaccine candidate; protein subunit-based Clinical VLA1553: Approved live-attenuated vaccine Programs Chi
Slide 5: Our Strategy to Become a Globally Recognized Vaccine Company
Our Strategy to Become a Globally Recognized Vaccine Company Contribute to a world in which no one dies or suffers from a vaccine preventable disease Maximize Integrated Biotech Capture Model Drive Vaccine R&D Upside Augment clinical pipeline to Commercial Growth Leverage proven R&D engine generate
Slide 6: Continued Product Sales Growth Fuels Investments into R&D
Continued Product Sales Growth Fuels Investments into R&D Commercial business expected to be cash-flow positive for 2025 155-1701 163 Pre-COVID IXCHIQ® (€ million) 145 Leveraging Infrastructure 130 Lean commercial infrastructure markets 3PP 115 multiple high-margin, specialty vaccines DUKORAL® COVID
Slide 7: VLA15 World's leading Lyme Disease Vaccine Candidate
VLA15 World’s leading Lyme Disease Vaccine Candidate
Slide 8: Lyme Disease Represents A Major Medical Need And Market Opportunity
Lyme Disease Represents A Major Medical Need And Market Opportunity No vaccine is currently available to prevent Lyme disease in humans Commercial opportunity for Valneva Annual Burden of Disease U.S. : ~476K cases Europe : >132K cases Severe Manifestations3 10-30% cases develop • Lyme carditis • Ly
Slide 9: World's Leading Vaccine Candidate Against Lyme Disease
World’s Leading Vaccine Candidate Against Lyme Disease VLA15: the only Lyme disease program in advanced clinical development today Vaccine Market Key Highlights Opportunity Milestones Multivalent, recombinant proteins Exclusive, worldwide On track for Phase 3 data partnership2 readout in H1 2026; Re
Slide 10: VLA15 Demonstrated Strong Immunogenicity Across 1,030 Adults and Children
VLA15 Demonstrated Strong Immunogenicity Across 1,030 Adults and Children Three Phase 2 studies1 optimized dose and schedule across age groups 2020 2021 2022 First positive First positive First positive immunogenicity data booster data pediatric data VLA15-201 VLA15-202 VLA15-221 • Immunogenic (all
Slide 11: Phase 3: Vaccination Completed; First Data Readout Upcoming
Phase 3: Vaccination Completed; First Data Readout Upcoming Pfizer aims to submit regulatory applications in U.S. and Europe in 20261 Tick Season 2023 Tick Season 2024 Tick Season 2025 VLA15 Cohort 1 Placebo Month 0 2 5-9 6-10 13 18 19 25 Primary series Booster VLA15 Efficacy Cohort 2 Read-out Place
Slide 12: VLA15 is a Compelling Opportunity
VLA15 is a Compelling Opportunity First-Mover Differentiated Compelling Strategic Fit Attractive Advantage in a yet De-Risked Target Population with Pfizer’s Vaccine Commercial Vaccine-“Naïve” Product Profile and Use Case Franchise Dynamics Market Only Lyme disease Proven MoA with Broad addressable
Slide 13: IXCHIQ / VLA1553 A Highly Differentiated single-shot Chikungunya Vaccine
IXCHIQ® / VLA1553 A Highly Differentiated single-shot Chikungunya Vaccine
Slide 14: Chikungunya: A Major Public Health Threat
Chikungunya: A Major Public Health Threat Mosquito-transmitted outbreak disease with potentially debilitating consequences • Often causes large, explosive outbreaks • Affecting up to 75% of the local population1 • Substantial quality-of-life and health-economic impact2 • Nearly half (43%) of those i
Slide 15: IXCHIQ: A Highly Differentiated single-shot Chikungunya Vaccine
IXCHIQ®: A Highly Differentiated single-shot Chikungunya Vaccine Vaccine Market Key Highlights Opportunity Milestones Live-attenuated: offers strong and Travelers Potential upcoming approval of long-lasting protection with a locally developed vaccine single shot Military VLA-1555 in Brazil Approved
Slide 16: CHIKV Vaccine Achieves Long-Lasting Immunogenicity with a Single Shot
CHIKV Vaccine Achieves Long-Lasting Immunogenicity with a Single Shot Differentiated vaccine shows rapid, persistent immunity across all age groups tested1,2,5 Immunogenicity Data Safety Data 99% Seroresponse3 Rate (SRR) after single Generally well tolerated by >3,600 adults and 754 vaccination → ma
Slide 17: IXCHIQ: Focused on Expanding Access, Label Extension, Product Profile
IXCHIQ®: Focused on Expanding Access, Label Extension, Product Profile Robust clinical program supported by CEPI grant1 Post-Marketing Effectiveness2 (Phase 4) To confirm effectiveness following licensure based on an immunological surrogate of protection and to optimize description of the safety pro
Slide 18: S4V2 World's Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
S4V2 World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
Slide 19: S4V2: Opportunity to Develop First-in-Class Vaccine for a Life-Threatening Disease
S4V2: Opportunity to Develop First-in-Class Vaccine for a Life-Threatening Disease Tetravalent bioconjugate vaccine with potential to cover up to ~85% of shigellosis infections1 Vaccine Market Key Highlights Opportunity Milestones World’s most clinically advanced Global market expected to exceed Pha
Slide 20: Valneva Gains Exclusive Worldwide Rights to Tetravalent Shigella Vaccine
Valneva Gains Exclusive Worldwide Rights to Tetravalent Shigella Vaccine Strategic partnership with LimmaTech Biologics (“LMTB”) Vaccine candidate “S4V2” Key Aspects Key Aspects of Partnership of Partnership World’s most clinically advanced tetravalent €10 million upfront payment to LMTB Shigellosis
Slide 21: Commercial Assessment of Shigella vaccine
Commercial Assessment of Shigella vaccine Shigella vaccine market estimated to peak at ~€500 million1 Children in endemic Traveler (~23%) Military (<1%) countries (~76%) 20-50% 30-100% 70-90% Recommendation (OOP-reimbursement) (Med-high risk destinations) (Med-high risk destinations Acceptance 30% 1
Slide 22: Financial Guidance & Outlook
Financial Guidance & Outlook
Slide 23: Valneva Remains Solidly Funded with Strong Financial Outlook
Valneva Remains Solidly Funded with Strong Financial Outlook 2025 Guidance Financial Outlook Product Sales: €155 - €170 million1,2; Commercial Continued revenue growth and cash flows from business expected to be cash-flow positive commercialized vaccines Total Revenues: €165 - €180 million Focused a
Slide 24: Valneva Outlook: Growth Drivers for 2026 and Beyond
Valneva Outlook: Growth Drivers for 2026 and Beyond VLA15 success case • Potential for sustained profitability upon potential approval and commercialization*, driven by substantial milestones and royalties starting in 2027 Growing commercial revenues • Near term: continued growth trajectory of IXIAR
Slide 25: Reaching Further, Where Most Needed
Reaching Further, Where Most Needed Our Vision: a world in which no one dies or suffers from a vaccine-preventable disease ESG Agenda Commercial vaccines with access routes for 100% Protecting Lives people in LMICs1 We develop vaccines for unmet medical needs – focusing on universal access 4 Clinica
Slide 26: Thank you
Thank you Merci Danke Tack valneva